It’s not just import of raw materials (active pharmaceutical ingredients, or APIs) from China that is giving sleepless nights to domestic pharma companies. Now, “illegal” import of drugs from Bangladesh and other neighbouring countries have added to their worries.from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/2Xt2OZR
